0001104659-21-090195.txt : 20210708 0001104659-21-090195.hdr.sgml : 20210708 20210708155135 ACCESSION NUMBER: 0001104659-21-090195 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210702 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20210708 DATE AS OF CHANGE: 20210708 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSYNERGY INC CENTRAL INDEX KEY: 0000715812 STANDARD INDUSTRIAL CLASSIFICATION: MEASURING & CONTROLLING DEVICES, NEC [3829] IRS NUMBER: 362880990 STATE OF INCORPORATION: IL FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-12459 FILM NUMBER: 211080158 BUSINESS ADDRESS: STREET 1: 55 WEST MONROE STREET STREET 2: STE 1200 CITY: CHICAGO STATE: IL ZIP: 60603 BUSINESS PHONE: 8479560471 MAIL ADDRESS: STREET 1: 55 WEST MONROE STREET STREET 2: STE 1200 CITY: CHICAGO STATE: IL ZIP: 60603 8-K 1 tm2121766d1_8k.htm FORM 8-K

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934

Date of Report (Date Earliest Event Reported) July 2, 2021

BIOSYNERGY, INC.

(Exact name of Registrant as specified in its charter)

Illinois	0-12459	36-2880990
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification)

1940 E. Devon, Elk Grove Village, Illinois 60007

(Address of principal executive offices)

Registrant’s telephone number, including area code: (847) 956-0471

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 8, 2021, Biosynergy, Inc. (“Biosynergy”) announced that Laurence C. Mead, Chief Operating Officer, Chief Financial Officer, Chief Accounting Officer and Treasurer, resigned from Biosynergy effective July 2, 2021. Fred K. Suzuki, President, Chairman of the Board, and Chief Executive Officer, will assume the duties and offices of Chief Financial Officer and Chief Accounting Officer on an interim basis.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIOSYNERGY, INC.

Date: July 8, 2021	By:	/s/ Fred K. Suzuki /s/
	Fred K. Suzuki, President